The value of re-sampling for patients who had failed non-invasive prenatal testing due to low cell-free fetal DNA fraction.
10.3760/cma.j.cn511374-20201119-00813
- Author:
Ganye ZHAO
1
;
Peng DAI
;
Shanshan GAO
;
Conghui WANG
;
Xuechao ZHAO
;
Lina LIU
;
Xiangdong KONG
Author Information
1. Genetics and Prenatal Diagnosis Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China. kongxd@263.net.
- Publication Type:Journal Article
- MeSH:
Aneuploidy;
Cell-Free Nucleic Acids/genetics*;
DNA/genetics*;
Female;
Fetus;
Humans;
Pregnancy;
Prenatal Diagnosis
- From:
Chinese Journal of Medical Genetics
2022;39(2):135-138
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To assess the value of re-sampling for patients who had failed non-invasive prenatal testing (NIPT) due to low cell-free fetal DNA (cffDNA) fraction.
METHODS:Clinical data of 20 387 patients undergoing NIPT test was reviewed. The patients were re-sampled when initial blood test did not yield a result due to cffDNA fraction. The results were analyzed, and the outcome of pregnancy was followed up.
RESULTS:Among all samples, 17 (0.08%) had failed to yield a result due to low cffDNA fraction, all of which accepted re-sampling. A result was attained in 16 cases, with a success rate of 94.12%. Only one sample had failed the re-test.
CONCLUSION:For patients who had failed the initial NIPT due to low cffDNA fraction, re-sampling should be considered with gestational week and ultrasound results taken into consideration.
